NCT02580032已完成不适用
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 252
- 试验地点
- 1
- 主要终点
- Changes in CGI (Clinician Global Impression Scale)
研究概览
简要总结
This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 4 Years 至 13 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained
- •Child population - treatment näive:
- •Confirmed diagnosis of Growth Hormone Deficiency (GHD) prior to enrolment as determined by a Growth Hormone (GH) stimulation test, defined as a peak GH level of 7.0 ng/ml or less. The GH stimulation test will be according to local clinical standards
- •Pre pubertal children age 9 to less than 13 years at enrolment
- •No prior exposure to GH therapy (GH-treatment naïve)
- •Annualized height velocity (HV) below the 25th percentile for Chronological Age (CA) (HV less than -0.7 SD scores) and sex according to the standards of Prader et al (1989)
- •Body Mass Index (BMI) percentile greater than 5th and below 95th percentile according to Centers for Disease Control and Prevention (CDC) BMI-for-age growth charts
- •Child population - maintenance patients:
- •Confirmed diagnosis of GHD prior to enrolment as determined by a GH stimulation test, defined as a peak GH level of 10.0 ng/ml or less. The GH stimulation test will be according to local clinical standards
- •Pre pubertal children age 9 to less than 13 years at enrolment
- •Body Mass Index (BMI) percentile greater than 5th and below 95th percentile according to Centers for Disease Control and Prevention (CDC) BMI-for-age growth charts
- •Parent/Guardian population - treatment näive:
- •Parent/Guardian of child with a confirmed diagnosis of GHD prior to enrolment as determined by a GH stimulation test, defined as a peak GH level of 7.0 ng/ml or less. The GH stimulation test will be according to local clinical standards
- •Parent/Guardian of pre pubertal child age 4 to less than 9 years at enrolment
- •Parent/Guardian of child with no prior exposure to GH therapy (GH-treatment naïve)
- •Parent/Guardian of child with annualized height velocity (HV) below the 25th percentile for CA (HV less than -0.7 SD scores) and sex according to the standards of Prader et al (1989)
- •Parent/Guardian of child with Body Mass Index (BMI) percentile greater than 5th and below 95th percentile according to Centers for Disease Control and Prevention (CDC) BMI-for-age growth charts
- •Parent/Guardian living in the same residence as the child at least 50% of the time
- •Parent/Guardian population - maintenance patients:
- •Parent/Guardian of child with confirmed diagnosis of GHD prior to enrolment as determined by a GH stimulation test, defined as a peak GH level of 10.0 ng/ml or less. The GH stimulation test will be according to local clinical standards
- •Parent/Guardian of pre pubertal child age 4 to less than 9 years at enrolment
- •Parent/Guardian of child with Body Mass Index (BMI) percentile greater than 5th and below 95th percentile according to Centers for Disease Control and Prevention (CDC) BMI-for-age growth charts
- •Parent/Guardian living in the same residence as the child at least 50% of the time
排除标准
- •Child population - treatment näive and maintenance patients:
- •Any clinically significant abnormality likely to affect growth or the ability to evaluate growth:
- •a) Chromosomal abnormalities and medical "syndromes", e.g. but not limited to Turner's syndrome, Laron syndrome, Noonan syndrome, or absence of GH receptors
- •b) Congenital abnormalities (causing skeletal abnormalities), e.g. but not limited to Russell-Silver Syndrome, skeletal dysplasia's
- •c) Significant spinal abnormalities including scoliosis, kyphosis and spina bifida variants - Children born small for gestational age (SGA - birth weight and/or birth length less than -2 SD for gestational age)
- •Children diagnosed with diabetes mellitus or fasting blood glucose greater than or equal to 126 mg/dl (7.0 mmol/L), or HbA1c greater than or equal to 6.5% at enrolment
- •Current inflammatory diseases (e.g. but not limited to arthritis, inflammatory bowel diseases) requiring systemic corticosteroid treatment or glucocorticoids treatment for longer than 2 weeks within the last 3 months prior to enrolment
- •Children requiring glucocorticoid therapy (e.g. asthma) who are taking a dose of greater than 400 µg/day of inhaled budesonide or equivalents for longer than 1 month the year prior to enrolment
- •Concomitant administration of other treatments that may have an effect on growth, e.g. but not limited to anabolic steroids and methylphenidate for attention deficit hyperactivity disorder (ADHD). Hormone replacement therapies (thyroxin, hydrocortisone, desmopressin) are allowed for inclusion
- •Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol
- •The subject and/or the parent/Legally Acceptable Representative (LAR) are likely to be non-compliant in respect to trial conduct, as judged by the investigator
- •Parent/Guardian population - treatment näive and maintenance patients:
- •Parent/Guardian of child with any clinically significant abnormality likely to affect growth or the ability to evaluate growth:
- •a) Chromosomal abnormalities and medical "syndromes", e.g. but not limited to Turner's syndrome, Laron syndrome, Noonan syndrome, or absence of GH receptors
- •b) Congenital abnormalities (causing skeletal abnormalities), e.g. but not limited to Russell-Silver Syndrome, skeletal dysplasia's
- •c) Significant spinal abnormalities including scoliosis, kyphosis and spina bifida variants - Parent/Guardian of child born small for gestational age (SGA - birth weight and/or birth length less than -2 SD for gestational age)
- •Parent/Guardian of child diagnosed with diabetes mellitus or fasting blood glucose greater than or equal to 126 mg/dl (7.0 mmol/L), or HbA1c greater than or equal to 6.5% at enrolment
- •Parent/Guardian of child with current inflammatory diseases (e.g. but not limited to arthritis, inflammatory bowel diseases) requiring systemic corticosteroid treatment or glucocorticoids treatment for longer than 2 weeks within the last 3 months prior to enrolment
- •Parent/Guardian of children requiring glucocorticoid therapy (e.g. asthma) who are taking a dose of greater than 400 µg/day of inhaled budesonide or equivalents for longer than 1 month the year prior to enrolment
- •Parent/Guardian of child with concomitant administration of other treatments that may have an effect on growth, e.g. but not limited to anabolic steroids and methylphenidate for attention deficit hyperactivity disorder (ADHD). Hormone replacement therapies (thyroxin, hydrocortisone, desmopressin) are allowed for inclusion
- •Parent/Guardian of child with any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol
- •The subject and/or the parent/LAR are likely to be non-compliant in respect to trial conduct, as judged by the investigator
结局指标
主要结局
Changes in CGI (Clinician Global Impression Scale)
时间窗: After the physician scheduled MCID assessment visit (variable between week 3 and week 11) and week 12 follow-up visit after initiation of treatment
次要结局
- Changes in PGI (Patient Global Impression Scale)(After the physician scheduled MCID assessment visit (variable between week 3 and week 11) and week 12 follow-up visit after initiation of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Effect of Growth Hormone in Children With Growth Hormone DeficiencyGrowth Hormone DisorderGrowth DisorderIdiopathic Short StatureGrowth Hormone Deficiency in ChildrenNCT00262249Novo Nordisk A/S173
已完成
3 期
Efficacy on Height in SGA Children Treated With Growth HormoneFoetal Growth ProblemSmall for Gestational AgeNCT00184756Novo Nordisk A/S151
已完成
4 期
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth RetardationFoetal Growth ProblemSmall for Gestational AgeNCT01697644Novo Nordisk A/S75
已完成
4 期
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.Chronic Kidney DiseaseChronic Renal InsufficiencyNCT00184769Novo Nordisk A/S16
已完成
不适用
Impact of GH Measurements on GHD DiagnosisGrowth Hormone DeficiencyNCT04508673University Hospital, Montpellier41